Search
KT-A261
go.drugbank.com/drugs/DB19317ExperimentalKT-A261 is an adeno-associated viral vector serotype 2 (AAV2) encoded to express adalimumab. It is being investigated for the treatment of noninfectious uveitis.
Prenylamine
go.drugbank.com/drugs/DB04825ApprovedWithdrawnPrenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.
BZL101
go.drugbank.com/drugs/DB05051InvestigationalBZL101 is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. BZL101 targets diseased cells while leaving normal cells healthy and intact.
Fleroxacin
go.drugbank.com/drugs/DB04576ExperimentalFleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseDiacetyl benzoyl lathyrol
go.drugbank.com/drugs/DB11260ApprovedIt is also reported to be a skin conditioning agent.
Mixtures: O HUI white-skin science white calming maskMito-4509
go.drugbank.com/drugs/DB05846ExperimentalIt is used to treat Parkinson's Disease, Alzheimer's Disease, Retinal Disorders and other neurologic Disorders.
Taberminogene vadenovec
go.drugbank.com/drugs/DB05011ExperimentalEG004 has completed a Phase II trial, this being the first part of the Phase II/III study for which it has received approval from the US Recombinant DNA Advisory Committee (RAC). … Taberminogene vadenovec (EG004) is a novel product consisting of a local delivery device and a gene-based medicine, being developed to prevent the blocking of veins and arteries that frequently occurs
Alkaline Phosphatase
go.drugbank.com/drugs/DB05768InvestigationalAP only acts locally in the colon to reduce the continuous inflammation of the colon by endotoxin from Gram-negative bacteria and extracellular ATP in UC patients.
MEM 1003
go.drugbank.com/drugs/DB05547InvestigationalMEM 10003 was under investigation in clinical trial NCT00257673 (Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease) for the treatment of Alzheimer's Disease
NN344
go.drugbank.com/drugs/DB05115ExperimentalThe product is intended for basal insulin treatment of diabetes mellitus. … NN344 is a neutral, soluble long-acting human insulin analogue with 24 hour coverage by once daily injection. NN344 has a very flat and predictable action profile.